Cardiovascular Disease and HIV: Pathophysiology, Treatment Considerations, and Nursing Implications

Crit Care Nurse. 2016 Oct;36(5):37-46. doi: 10.4037/ccn2016839.

Abstract

HIV infection has progressed from an acute, terminal disease to a chronic illness with cardiovascular disease as the leading cause of death among persons living with HIV. As persons living with HIV infection continue to become older, traditional risk factors for atherosclerosis compounded by the pathophysiological effects of HIV infection and antiretroviral therapy markedly increase the risk for cardiovascular disease. Further, persons living with HIV are also at high risk for cardiomyopathy. Critical care nurses must recognize the risk factors for cardiovascular disease and the pathophysiology and complex treatment options in order to manage care of these patients and facilitate multidisciplinary collaboration. Two case studies are used to highlight the treatment options and nursing considerations associated with cardiovascular disease among persons living with HIV.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Anti-Retroviral Agents / administration & dosage*
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / nursing
  • Cardiovascular Agents / administration & dosage
  • Coronary Disease / complications
  • Coronary Disease / diagnosis
  • Coronary Disease / drug therapy*
  • Coronary Disease / nursing
  • Critical Care Nursing / methods*
  • Disease Management*
  • Drug Therapy, Combination
  • Follow-Up Studies
  • HIV Infections / complications
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy*
  • HIV Infections / nursing
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Male
  • Middle Aged
  • Monitoring, Physiologic / methods
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Anti-Retroviral Agents
  • Cardiovascular Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors